A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Clinical trial NCT06662786 · RECRUITING

Trial details

NCT number: NCT06662786
Sponsor: Janssen Research & Development, LLC
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Colorectal Neoplasms

Start date: 2024-10-18
Primary completion: 2028-12-15
Enrollment: 1000

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.